Skip to main content

Table 3 Survival probabilities from the model outcomes and trial data

From: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

  Model outcome Trial data Difference
Disease-free survival    
 Surgery only at 3 years 60.8% 59.6% (95% CI, 54.9 - 64.3%) 1.2%
 Adjuvant with S-1 at 3 years 72.3% 72.2% (95% CI, 67.9 - 76.4%) 0.1%
 Adjuvant with XELOX strategy at 3 years 75.0% 74% (95% CI, 69 - 79%) 1.0%
 Surgery only at 5 years 51.2% 53.1% (95% CI, 48.7 - 57.4%) −1.9%
 Adjuvant with S-1 at 5 years 64.6% 65.4% (95% CI, 61.2 - 69.5%) −0.8%
 Adjuvant with XELOX strategy at 5 years 67.9% 68% −0.1%
Overall survival    
 Surgery only at 3 years 72.2% 70.1% (95% CI, 65.5 - 74.6%) 2.1%
 Adjuvant with S-1 at 3 years 80.4% 80.1% (95% CI, 76.1 - 84.0%) 0.3%
 Adjuvant with XELOX strategy at 3 years 80.7% 83% (95% CI, 79 - 87%) −2.3%
 Surgery only at 5 years 60.9% 61.1% (95% CI, 56.8 - 65.3%) −0.2%
 Adjuvant with S-1 at 5 years 71.8% 71.7% (95% CI, 67.8 - 75.7%) 0.1%
 Adjuvant with XELOX strategy at 5 years 72.1% 78% −5.9%